Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02538198 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lenalidomide Maintenance in Plasma Cell Myeloma

StatusActive, Not Recruiting
PhasePhase 2
Started2015-08-31
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 11 months later Aug 2026 → Aug 2027
See other at-risk trials from Memorial Sloan Kettering Cancer Center

Amendment history

2026-09-26
critical
Primary completion pushed: 2026-08 → 2027-08
Completion pushed: 2026-08 → 2027-08
2026-07-02
minor
Study Status v32
Re-verified, no change to tracked fields
2025-07-02
minor
Study Status v31
Primary completion date2025-08→2026-08
Completion date2025-08→2026-08
2024-07-02
minor
Study Status v30
Primary completion date2024-08→2025-08
Completion date2024-08→2025-08
2023-06-29
minor
Study Status, Contacts/Locations v29
Primary completion date2023-08→2024-08
Completion date2023-08→2024-08
Study sites6 entries, revised
MemoralMemorial Sloan Kettering Cancer Center
Show 28 earlier versions
2022-09-01
minor
Study Status v28
Primary completion date2022-08→2023-08
Completion date2022-08→2023-08
2021-09-01
minor
Study Status v27
Primary completion date2021-08→2022-08
Completion date2021-08→2022-08
2020-10-05
minor
Study Status, Contacts/Locations v26
Re-verified, no change to tracked fields
2020-06-04
minor
Study Status, Contacts/Locations v25
Study sites7→6
2020-03-24
minor
Study Status v24
Primary completion date2020-08→2021-08
Completion date2020-08→2021-08
2019-11-07
minor
2 amendments v22-v23
2 re-verifications since 2019-10-22, no change to tracked fields
2019-08-14
notable
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v21
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 100→confirmed 108
Study sitesdetails revised at 7 of 7 sites
2019-04-04
minor
Study Status, Contacts/Locations v20
Primary completion date2019-08→2020-08
Completion date2019-08→2020-08
Study sitesdetails revised at 1 of 7 sites
2019-03-13
minor
Study Status, Contacts/Locations v19
Study sites6→7
2018-12-14
minor
2 amendments v17-v18
2 re-verifications since 2018-09-25, no change to tracked fields
2018-08-20
minor
Study Status v16
Primary completion date2018-08→2019-08
Completion date2018-08→2019-08
2018-08-01
minor
Study Status, Contacts/Locations v15
Study sites5→6
2018-04-25
minor
3 amendments v12-v14
3 re-verifications since 2017-12-08, no change to tracked fields
2017-07-05
minor
Study Status, Contacts/Locations v11
Study sitesdetails revised at 1 of 5 sites
2017-03-13
minor
Study Status v10
Primary completion date2017-08→2018-08
Completion date2017-08→2018-08
2017-01-25
minor
Study Status v9
Completion datenot stated→2017-08
Start date2015-08→2015-08-31
2016-11-18
minor
Study Status v8
Re-verified, no change to tracked fields
2016-10-28
minor
Study Status, Study Design v7
Enrollment target50→100
2016-09-20
minor
Study Status, Arms and Interventions, Contacts/Locations v6
Study sites6→5
2016-08-30
minor
Study Status v5
Re-verified, no change to tracked fields
2016-02-26
minor
Study Status, Eligibility v4
Eligibility criteria+23 characters
[...] eptable Birth Control Methods. Patients must be able to take daily prophylactic anticoagulation medication, such as: aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin) or other medications as clinically indicated. Patient must understand and voluntarily sign an informed c [...]
2015-12-10
minor
Study Status v3
Re-verified, no change to tracked fields
2015-10-29
minor
Study Status, Eligibility v2
Eligibility criteria-2 characters
[...] e measured CrCl must also be ≥ 40 ml/min. Total bilirubin ≤ 1.52 mg/dL, AST (SGOT) and ALT (SGPT) ≤ 3 x ULN All study partic [...]
2015-09-28
minor
Study Status, Conditions, Eligibility v1
Eligibility criteria-23 characters
Inclusion Criteria: Patients with multipleplasma cell myeloma treated with induction therapy or re-induction ther [...] Exclusion Criteria: Patients with progressive or refractory MMplasma cell myeloma, as defined by International Myeloma Workshop Consensus Pan [...] ma. Permitted concurrent therapies include: Bisphosphonates Radiotherapy to single stable disease site Plasma cell leukemia Pregnant or breastfeeding females. Beca [...]
2015-08-31
minor
Original filing
This is a Phase 2 study to assess the good and bad effects of maintenance therapy on patients who have been treated for myeloma and no longer show signs of this type of cancer.
Trial Details
NCT Number NCT02538198
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Plasma Cell Myeloma
Enrollment 108 participants
Start Date 2015-08-31
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-09-25